Addex Therapeutics Schedules Q3 2025 Results Call as Key Pipeline Programs Advance

Upcoming Q3 Results Call to Shed Light on Business Momentum

Addex Therapeutics is set to release its third-quarter 2025 financial results and provide a business update on December 4, 2025. Investors, analysts, and the media are invited to join the conference call and webcast at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT), where CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will review financial performance and discuss progress across the company’s clinical pipeline.

Focused Pipeline with Expanding Partnership Potential

The Geneva-based biotech specializes in developing novel small molecule allosteric modulators for neurological disorders. Addex’s lead candidate, dipraglurant, a negative allosteric modulator (NAM) targeting mGlu5, is positioned for future development in brain injury recovery—including post-stroke and traumatic brain injury. This update is anticipated to include development timelines and clinical outlooks for these core indications.

Collaboration is a growing part of the Addex story. Its partnership with Indivior is progressing, as Indivior’s GABAB PAM candidate for substance use disorders has completed IND enabling studies. Additionally, Addex is independently advancing another GABAB PAM program focused on chronic cough, demonstrating the company’s multi-pronged approach to neurology therapeutics.

Diversified Exposure via Spinouts and Investments

Beyond its core portfolio, Addex holds a 20% equity stake in Neurosterix LLC—a private company advancing programs in schizophrenia, psychosis, and mood-related disorders, such as the M4 PAM and mGlu7 NAM candidates. This stake allows Addex to participate in innovation while mitigating operational risk. Addex is also invested in Stalicla, a Swiss firm focused on precision medicine for neurodevelopmental and neuropsychiatric disorders, broadening its footprint in cutting-edge CNS drug discovery.

What to Watch for During the Q3 Update

For investors, this upcoming financial report is more than just a look at the books. It offers an opportunity to hear updates on pipeline advancement, milestones from partners, and potential next steps for asset development or commercialization. Addex’s diversified portfolio and stake in innovation through partnerships may prove especially relevant given current volatility and interest in neurology-focused biopharma companies.

The conference call registration details and further company information are available via Addex’s investor relations page. Participants can expect clarity on the clinical trajectory of key programs, financial stability, and updates on how external partnerships may unlock further value for shareholders.

Takeaway: Eyes on Clinical and Corporate Progress in December

While it’s always risky to draw sweeping conclusions from a single earnings announcement, Addex’s ongoing investments in its pipeline, spinout companies, and collaborations offer multiple catalysts for the quarters ahead. For those tracking emerging players in neurological therapeutics, December 4 may provide essential signals on Addex’s future direction and strategic vision.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI